# A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

> **NCT03352765** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 28 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** rituximab
- **DRUG:** bendamustine
- **DRUG:** melphalan
- **PROCEDURE:** Autologous Stem Cell Transplantation (ASCT)

## Key facts

- **NCT ID:** NCT03352765
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-20
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352765, "A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03352765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*